EUVIMEDEUVIMED entdecken
Crossref

The Usefulness of Serum Interleukin-6 as a Predictor of Response to Atezolizumab plus Bevacizumab Combination Treatment in Hepatocellular Carcinoma

Takanori Mukozu, Hidenari Nagai, Hideki Nagumo, Kunihide Mohri, Naoyuki Yoshimine, Kojiro Kobayashi, Yu Ogino, Teppei Matsui, Yasuko Daido, Noritaka Wakui, Koichi Momiyama, Koji Higai und 2 weitere

Oncology · 2024

DOI: 10.1159/000541372 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Oncology, 2024. Verfasst von Takanori Mukozu und 13 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, Department of Internal Medicine (Omori), School of Medicine, Faculty of Medicine, Toho University, Tokyo…. Hauptthemen laut MEDLINE: Interleukin-6, Carcinoma, Hepatocellular, Liver Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 40 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

In atezolizumab plus bevacizumab (Atezo/Bev) combination treatment, both drugs act on the immune system. Previously, we reported that immunological changes after Atezo/Bev administration for unresectable hepatocellular carcinoma (uHCC) revealed significant alterations in interleukin (IL)-6, soluble IL-2 receptor, tumor necrosis factor-alpha, and programmed cell death-1 levels. Among these variable factors, serum levels of IL-6 can be easily measured on a commercial basis. Therefore, this study aimed to investigate the utility of serum IL-6 as a predictor of tumor response to Atezo/Bev treatment for uHCC.

Method

The study included 44 patients with HCC treated with Atezo/Bev. Blood samples were collected before and 3 weeks after treatment, and tumor response was assessed using contrast-enhanced computed tomography 6 weeks after treatment.

Results

Significant changes in serum IL-6 levels were observed in patients treated with Atezo/Bev as first-line therapy but not in those treated with it as second-line or later-line therapy. In patients treated with Atezo/Bev as first-line therapy, serum IL-6 levels increased significantly after treatment in patients with a complete or partial response but not in patients with stable or progressive disease. Furthermore, compared to other tumor markers such as alpha-fetoprotein, Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein, and des-gamma-carboxyprothrombin, serum IL-6 levels exhibited the highest sensitivity in predicting tumor response during the treatment period.

Conclusion

In patients with uHCC treated with Atezo/Bev, serum IL-6 levels could serve as a potential predictor of tumor response. Elevated levels after treatment may indicate a favorable tumor response and prognosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Interleukin-6Carcinoma, HepatocellularLiver NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsHumansAntibodies, Monoclonal, HumanizedMaleFemaleBevacizumabMiddle AgedAgedBiomarkers, TumorTreatment OutcomeAdult

Stichwörter der Autor:innen

AtezolizumabBevacizumabHepatocellular carcinomaSerum interleukin-6

Substanzen

Interleukin-6atezolizumabAntibodies, Monoclonal, HumanizedBevacizumabIL6 protein, humanBiomarkers, Tumor

Autor:innen und Institutionen

  • Division of Gastroenterology and Hepatology, Department of Internal Medicine (Omori), School of Medicine, Faculty of Medicine, Toho University, Tokyo, Japan.
  • Department of Medical Biochemistry, Faculty of Pharmaceutical Sciences, Toho University, Chiba, Japan.

Zitieren

APA

Mukozu, T., Nagai, H., Nagumo, H., Mohri, K., Yoshimine, N., Kobayashi, K., Ogino, Y., Matsui, T., Daido, Y., Wakui, N., Momiyama, K., Higai, K., Matsuda, T., & Igarashi, Y. (2024). The Usefulness of Serum Interleukin-6 as a Predictor of Response to Atezolizumab plus Bevacizumab Combination Treatment in Hepatocellular Carcinoma. Oncology. https://doi.org/10.1159/000541372

Vancouver

Mukozu T, Nagai H, Nagumo H, Mohri K, Yoshimine N, Kobayashi K, et al. The Usefulness of Serum Interleukin-6 as a Predictor of Response to Atezolizumab plus Bevacizumab Combination Treatment in Hepatocellular Carcinoma. Oncology. 2024. doi:10.1159/000541372

BibTeX
@article{Mukozu2024,
  author = {Mukozu, Takanori and Nagai, Hidenari and Nagumo, Hideki and Mohri, Kunihide and Yoshimine, Naoyuki and Kobayashi, Kojiro and Ogino, Yu and Matsui, Teppei and Daido, Yasuko and Wakui, Noritaka and Momiyama, Koichi and Higai, Koji and Matsuda, Takahisa and Igarashi, Yoshinori},
  title = {The Usefulness of Serum Interleukin-6 as a Predictor of Response to Atezolizumab plus Bevacizumab Combination Treatment in Hepatocellular Carcinoma},
  journal = {Oncology},
  year = {2024},
  doi = {10.1159/000541372}
}
Kostenlos starten →